Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
54.61
+0.47 (0.86%)
Nov 21, 2024, 2:29 PM EST - Market open
Keros Therapeutics Revenue
Keros Therapeutics had revenue of $388.00K in the quarter ending September 30, 2024, with 4,750.00% growth. This brings the company's revenue in the last twelve months to $651.00K, up 8,037.50% year-over-year. In the year 2023, Keros Therapeutics had annual revenue of $151.00K.
Revenue (ttm)
$651.00K
Revenue Growth
+8,037.50%
P/S Ratio
n/a
Revenue / Employee
$4,787
Employees
136
Market Cap
2.21B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 2.47B |
Premier | 1.33B |
CONMED | 1.29B |
Omnicell | 1.06B |
UFP Technologies | 461.85M |
NewAmsterdam Pharma Company | 33.59M |
Geron | 29.48M |
IDEAYA Biosciences | 3.92M |
KROS News
- 14 days ago - Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewsWire
- 15 days ago - Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 3 months ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 3 months ago - Keros Therapeutics Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth - Benzinga
- 5 months ago - Keros Therapeutics Announces Leadership Updates - GlobeNewsWire
- 5 months ago - Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association - GlobeNewsWire
- 5 months ago - Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers - Seeking Alpha